Your browser doesn't support javascript.
loading
Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany.
Michel, Alexander; Lecomte, Coralie; Ohlmeier, Christoph; Raad, Hanaya; Basedow, Frederike; Haeckl, Dennis; Beier, Dominik; Evers, Thomas.
Afiliación
  • Michel A; Bayer Consumer Care AG, Pharmaceuticals, Peter Merian Straße 84, 4052, Basel, Switzerland. alexander.michel@bayer.com.
  • Lecomte C; Aetion Inc., New York, USA.
  • Ohlmeier C; Bayer AG, Berlin, Germany.
  • Raad H; Aetion Inc., New York, USA.
  • Basedow F; InGef-Institute for Applied Health Research, Berlin GmbH, Berlin, Germany.
  • Haeckl D; WIG2 GmbH, Leipzig, Germany.
  • Beier D; InGef-Institute for Applied Health Research, Berlin GmbH, Berlin, Germany.
  • Evers T; Bayer AG, Wuppertal, Germany.
Am J Cardiovasc Drugs ; 24(3): 409-418, 2024 May.
Article en En | MEDLINE | ID: mdl-38573461
ABSTRACT

BACKGROUND:

Data are limited regarding guideline-directed medical therapy (GDMT) treatment patterns in patients with worsening heart failure (HF).

METHODS:

We used administrative claims databases in Germany and the USA to conduct a retrospective cohort study of patients with worsening HF. Two cohorts of patients with prevalent HF and a HF hospitalization (HFH) from 2016 to 2019, alive at discharge (N = 75,140 USA; N = 47,003 Germany) were identified. Index date was the first HFH during the study period. One-year HF rehospitalization and mortality rates were calculated and a composite endpoint of both outcomes assessed using Kaplan-Meier estimation. We evaluated HF medication patterns in the 6 months before and after the index date. New users of a HF medication (at discharge/after index HFH) were followed for 1 year to evaluate persistence (no treatment gaps > 2 months)

RESULTS:

One-year HF rehospitalization rates were 36.2% (USA) and 47.7% (Germany). One year mortality rates were 30.0% (USA) and 23.0% (Germany), and the composite endpoint (mortality/HF rehospitalization) was reached in 55.1 % (USA) and 56.6% (Germany). Kaplan-Meier plots showed the risk for the composite endpoint was high in the early post discharge period. Comparison of patterns pre- and postindex HFH showed some increase in use of mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitor (ARNI), and triple therapy; use of angiotensin-converting enzyme (ACE) inhibitor/ angiotensin receptor blocker (ARB) plus beta-blockers remained constant/slightly declined; < 20% patients received triple therapy (ACE inhibitor/ARB plus beta-blocker plus MRA). A third of patients were new users; 1 year persistence rates were often low.

CONCLUSIONS:

Morbidity, mortality, and rehospitalization risk is high among patients with worsening HF; uptake and continuation of GDMT is suboptimal.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Cardíaca Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Am J Cardiovasc Drugs Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Nueva Zelanda

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Insuficiencia Cardíaca Límite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: America do norte / Europa Idioma: En Revista: Am J Cardiovasc Drugs Asunto de la revista: ANGIOLOGIA / CARDIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Nueva Zelanda